Roche may share Avastin brain-cancer data after conflicting data

Roche (RHHBF) and a group of external investigators could share raw data from two trial's of the company's Avastin drug that provide conflicting evidence about how beneficial it is for patients with a brain cancer called glioblastoma.

Avastin didn't help patients live longer in either study, but in one of them, it does seem to have improved or maintained quality of life and brain function. That wasn't the case in the other trial.

If Avastin can improve quality of life and brain function, says Howard Fine of the New York University Cancer Institute, "a strong argument can be made for its use as part of the initial treatment of glioblastoma, regardless of its effect on survival."

However, such considerations would be new ground for the FDA, says Fine.

From other sites
Comments (1)
  • taylor473
    , contributor
    Comments (6) | Send Message
    err... weren't inconsistent results the reason for the FDA withdrawal of the Avastin label for breast cancer? Failure to improve survival but improved PFS/other endpoints has dogged interpretation of data for this drug. Even if glioblastoma is different from breast cancer in terms of patient-centric endpoints the weight of data splits 50:50... very tricky decision...
    20 Feb 2014, 03:14 PM Reply Like
DJIA (DIA) S&P 500 (SPY)
ETF Screener: Search and filter by asset class, strategy, theme, performance, yield, and much more
ETF Performance: View ETF performance across key asset classes and investing themes
ETF Investing Guide: Learn how to build and manage a well-diversified, low cost ETF portfolio
ETF Selector: An explanation of how to select and use ETFs